The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure

Abstract

Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development of natriuretic peptide (NP) through inhibition of the neprilysin enzyme is the therapeutic target in HF. Treatment with sacubitril/valsartan has been shown to significantly reduce mortality and hospitalization and rehospitalization rates for HF compared with enalapril. Sacubitril/valsartan may provide significant additional benefit in HF patients.